Cellosaurus RD (CVCL_1649)

Cell line name RD
Synonyms R D; RD-2; RD 2; 130T; 130-T; 130 T; TE-32; TE 32; TE32; TE 32.T; Te 32.T
Accession CVCL_1649
Secondary accession CVCL_S332
Resource Identification Initiative To cite this cell line use: RD (RRID:CVCL_1649)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Doubling time: 23 hours (PubMed=20922763).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Embryonal rhabdomyosarcoma (NCIt: C8971)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_0350 (IN157); CVCL_IU94 (RD/12); CVCL_IU87 (RD/18); CVCL_DP30 (RD.TG6); CVCL_1756 (TE 671)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; COG; ECACC; JCRB; KCLB; PubMed=20922763; PubMed=21948088

Markers:
AmelogeninX
CSF1PO10,11
D13S31713
D16S53910,11
D18S5113,18
D19S43311,14
D21S1128,29
D2S133817,23
D3S135815,17
D5S81811
D7S8208,12
D8S117911,15
FGA20,21
Penta D11,13
Penta E12
TH019.3
TPOX9
vWA18
Web pages http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://en.vircell.com/products/rd-cell-line/
http://tcpaportal.org/mclp/
Publications

PubMed=4241949; DOI=10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M
McAllister R.M., Melnyk J., Finkelstein J.Z., Adams E.C. Jr., Gardner M.B.
Cultivation in vitro of cells derived from a human rhabdomyosarcoma.
Cancer 24:520-526(1969)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2302710
Ozkaynak M.F., Nolta J., Parkman R.
In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide.
Cancer Res. 50:1455-1458(1990)

PubMed=8275086; DOI=10.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Clin. Cancer Res. 17:7324-7336(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23578105; DOI=10.1111/cas.12173
Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R., Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y., Ogawa S.
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Cancer Sci. 104:856-864(2013)

PubMed=23882450; DOI=10.3389/fonc.2013.00183
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183-183(2013)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections AddexBio; C0035001/4950
ATCC; CCL-136
ATCC; CRL-7713 - Discontinued
ATCC; CRL-7731 - Discontinued
BCRC; 60113
BCRJ; 0260
CLS; 300401/p527_RD
ECACC; 85111502
IZSLER; BS TCL 57
JCRB; JCRB9072
KCLB; 10136
Cell line databases/resources CLDB; cl4119
CLDB; cl4120
CLDB; cl4121
CLDB; cl4122
CLDB; cl4123
CLDB; cl4124
CLDB; cl4125
CLDB; cl4126
CLDB; cl4127
CCLE; RD_SOFT_TISSUE
CCRID; 3111C0001CCC000293
CCRID; 3111C0002000000079
CCRID; 3131C0001000700045
Cosmic-CLP; 909264
GDSC; 909264
IGRhCellID; RD
LINCS_LDP; LCL-1411
TOKU-E; 2986
Ontologies BTO; BTO:0005377
CLO; CLO_0008693
CLO; CLO_0008770
EFO; EFO_0002315
Biological sample resources BioSample; SAMN01821591
BioSample; SAMN01821716
BioSample; SAMN03472710
Chemistry resources ChEMBL-Cells; CHEMBL3307547
ChEMBL-Targets; CHEMBL614144
Gene expression databases GEO; GSM185149
GEO; GSM186446
GEO; GSM219726
GEO; GSM887528
GEO; GSM888610
GEO; GSM1670368
GEO; GSM1676309
GEO; GSM1701643
Polymorphism and mutation databases Cosmic; 724833
Cosmic; 801358
Cosmic; 801760
Cosmic; 802045
Cosmic; 909264
Cosmic; 1037298
Cosmic; 1048111
Cosmic; 1097753
Cosmic; 1309330
Cosmic; 1509195
Cosmic; 1620036
Cosmic; 1718099
Cosmic; 2296987
Cosmic; 2301590
Cosmic; 2355912
Proteomic databases PRIDE; PXD000589